A busy and challenging year.
Release time:
2021-03-01
Group Company 2020 Outstanding Employee Pharmaceutical Company Peak Pharmaceutical Factory Wang Junyang
Looking back on this year's work, it was busy and full of challenges. The preparation workshop concentrates on the production of multiple products, especially when the eye drops / ear liquid line and the API production line are produced at the same time, the time is tight and the production task is heavy. As a craftsman, on-site inspection and supervision are under great pressure. I reasonably allocated time and completed various process control to ensure the smooth progress of production tasks.
This year, in addition to completing the production tasks, the workshop also carried out a number of technological innovation and transformation projects. In the artificial bezoar technological transformation project, I participated in the transformation of the condensate collection device of the vacuum pipeline of the drying equipment, the on-site inspection of the manufacturer of the ultrasonic oscillating screen and the equipment selection, and improved the efficiency of drying and sieving. The sieving time was reduced from 14 hours per batch to 3 hours, and ensured that the sieving and the next batch of feeding could be completed in one shift, thus improving the production efficiency and reducing the production cost, shorten the production cycle. In the technical renovation project of the water for injection system pipeline and the liquid distribution system of the eye drop line, I worked overtime to debug and optimize the program for many times according to the production process of the product, and repeatedly tested and confirmed each key parameter. In the process, many deficiencies were found in the program, such as the problem that the bottom valve of the liquid storage tank was not opened and the liquid medicine could not be delivered to the production line under the automatic medicine delivery program of the liquid distribution system, timely report to the leaders and conduct feedback communication with factory engineers on site, and remove the problems and defects one by one until the production requirements are met. In the new project of ethylene oxide sterilization process, I was responsible for the debugging and optimization of the equipment and the technical exchange with the engineers of the manufacturer. In the follow-up verification work, I was responsible for the drafting of the verification scheme, the development of the verification work and the deployment of personnel, and successfully completed the relevant verification work to ensure that the production tasks were carried out on time. In the consistency evaluation of sodium hyaluronate eye drops and the trial production of tamoxifin eye drops and moxifloxacin hydrochloride eye drops, I participated in the whole process from the first draft of the research plan to the formation of standard documents conforming to pharmaceutical companies. I also participated in the whole process to guide the operation feasibility of the process flow, the conformity of equipment and technology, the rationality of sampling, and actively participated in the analysis and discussion of abnormal conditions, my opinions and ideas were given and adopted, the problems were solved in time, and the verification batch production of consistency evaluation and the trial production of new products were successfully completed.
I believe that the new year will also be full of opportunities and challenges. In the following work, I will also uphold the enterprise spirit of "unity and struggle, realistic and innovative, determined to be the top, and bravely climb the peak " , constantly improve my quality awareness, strengthen professional knowledge reserve, improve working ability, stick to my job and strive for innovation, to ensure the quality of drugs as the fundamental, to improve production efficiency for the purpose, improve the production process, save production costs. Keep in mind the purpose of the enterprise, contribute to the creation of "Centennial Peak " with more standardized management, more effective execution and more rigorous attitude with full work enthusiasm and indomitable fighting spirit.
(according to Wang Junyang's speech at the summary and commendation meeting of the pharmaceutical company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page